Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Passage Bio, Inc.
Market Cap
$13.24M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.51M
Net Profit Margin
-3972.87%
TTM Avg
-1209.50%
3Y Avg
-3598.61%
5Y Avg
-2399.08%
Market Cap
$13.66M
Net Profit Margin
-8716.77%
TTM Avg
-1649.40%
3Y Avg
-960.30%
5Y Avg
-749.49%
Market Cap
$12.78M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$12.77M
Net Profit Margin
-48.94%
TTM Avg
-40.16%
3Y Avg
-67.25%
5Y Avg
-58.35%
Market Cap
$13.74M
Net Profit Margin
-651.27%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.86M
Net Profit Margin
-1303.40%
TTM Avg
-1281.42%
3Y Avg
-1220.10%
5Y Avg
-1266.64%
Market Cap
$12.52M
Net Profit Margin
-804.37%
TTM Avg
-21365.78%
3Y Avg
-11028.80%
5Y Avg
-7352.54%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Passage Bio, Inc. (PASG) | $13.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Optimi Health Corp. (OPTH)vs › | $13.51M | -3972.87% | -1209.50% | -3598.61% | -2399.08% |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | -8716.77% | -1649.40% | -960.30% | -749.49% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | -48.94% | -40.16% | -67.25% | -58.35% |
| IN8bio, Inc. (INAB)vs › | $13.71M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.74M | -651.27% | 0.00% | 0.00% | 0.00% |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -1303.40% | -1281.42% | -1220.10% | -1266.64% |
| Dare Bioscience, Inc. (DARE)vs › | $12.52M | -804.37% | -21365.78% | -11028.80% | -7352.54% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.10M | N/A | N/A | N/A | N/A |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
